Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Celgene $500 Million Notes Offering
Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million…
Spark Therapeutics Follow-On Offering
Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5…
Davis Polk Advises Accuray Incorporated on Its Private Exchange Offer
Davis Polk advised Accuray Incorporated in connection with a private exchange of approximately $47 million aggregate…
$3.1 Billion Financing for inVentiv’s Merger with INC Research
Davis Polk advised the administrative agent in connection with a $3.1 billion best-efforts financing comprised of a $1…
Davis Polk Advises PharMerica on Its Acquisition by KKR and Walgreens
Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company…
Sienna Biopharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of…
LabCorp Acquires Chiltern
Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to LabCorp in connection with its approximately $1.2…
Biotoscana Investments $377.7 Million Initial Public Offering
Davis Polk advised Biotoscana Investments S.A. and the selling shareholders in connection with an initial public offering of…
Davis Polk Advises Pernix Therapeutics Holdings, Inc. on Its Refinancing Transactions
Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with a series of refinancing transactions that are…
Kala Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public…